
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.

The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.

The US lost measles elimination status after 26 years; CDC and partners plan to regain it via MMR vaccination and $100M in health department funding.

At ACAAI 2026, 93.6% of pediatric biologic prescriptions needed prior authorization, 39.3% were denied, and approval took a mean of 33 days.

US preterm birth rate held at 10.4%, earning a fifth straight D+ from March of Dimes; maternal deaths fell, but racial disparities persist.

In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.

Data presented at NSGC 2026 tie maternal autoantibody combinations to a non-genetic autism subtype with high recurrence risk in later-born siblings.

Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.

Novo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.

In STEP Young, semaglutide cut BMI 13.5% at 68 weeks vs a 2.7% rise with placebo in children aged 6 to <12 years with obesity.

In this teaching case, an 18-year-old develops severe anxiety 2 months after stopping long-term fluoxetine because of hyperprolactinemia, raising the question of whether her symptoms reflect antidepressant withdrawal or relapse.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Schools without stock epinephrine were over 4 times as likely to lack a device in an allergic emergency, a survey of 349 school nurses found.

In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).

Non-English-speaking families were far less likely to introduce peanut by 6 months (OR, 0.21) in a 3,170-child study presented at ACAAI 2026.

In an ACAAI 2026 survey, 85% of clinicians knew food allergy panels often yield false positives, yet many ordered them for unvalidated uses.

Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.

Classroom engagement scores in digital gradebooks predicted substance use by eighth grade better than GPA (cross-validated AUC, 0.79 vs 0.63).

Children living more than 60 miles from their surgical hospital had higher complication odds and longer stays after common procedures.

Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.

Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.

CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.

Julie Sweetland, PhD, shares strategies to improve vaccine conversations by explaining the science, acknowledging parental concerns, and building trust.

A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.

FDA is investigating tumor reports after Zolgensma for SMA, including 2 confirmed cases of vector integration near the GLI1 oncogene.

Jon Matthew Farber, MD, shares his thoughts on the use of noninvasive brain stimulation for ADHD.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.

In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.

New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.

Jessica Nash, MD, IBCLC, shares strategies for assessing breastfeeding, identifying latch problems, and connecting families with lactation resources.